Vivos Therapeutics, Inc. - 8-K Filing
Vivos Therapeutics extended a strategic financing agreement with Streeterville Capital, LLC from June 15, 2026, to August 31, 2026. Under the terms, up to $4.5 million of outstanding debt will be converted into perpetual non-convertible preferred stock and common shares once Vivos raises at least $2.6 million in financing. (Items: 1.01 Entry into a Material Definitive Agreement, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $VVOS